The aim of the study was to determine the efficacy and @entity137 of alternate week concurrent @entity1487 , @entity1862 , and @entity900 with radiotherapy for locally advanced @entity788 . @entity1 received @entity1487 , @entity1862 and @entity900 with radiotherapy on an alternate week basis. Chemoradiotherapy was given day 1-5, and no therapy given day 6-14 for each 14 day cycle. Chemotherapy doses were as follows: @entity1862 1 mg every 12 h starting day 0, @entity1487 800 mg/m(2)/day for 5 days starting day 1, and @entity900 20 mg/m(2) daily for 5 days every other cycle. A radiation dose of 6000 cGy was prescribed. Acute @entity137 were monitored and therapy modified for hematologic @entity137 . Nine @entity1 enrolled, however eight were evaluable; one @entity1 expired prior to therapy. The median radiation dose delivered was 5540 cGy. Sixty-three percent required a chemotherapy dose reduction. Fifty percent achieved local control by radiographic imaging after completion of therapy. Median survival was 12 months. Acute @entity137 included: 38% grade 2-3 @entity390 , 37% grade 2-3 @entity391 , 63% grade 2-3 @entity33 , 63% grade 2-3 @entity1398 , and 88% grade 3-4 @entity882 . Other sequelae included @entity8566 , @entity1150 , @entity393 , @entity410 , and @entity448 . @entity1 achieved the same median survival as compared to other reported studies of radiation therapy with single agent @entity1487 . We do not recommend this protocol due to the significant @entity137 . Future studies to incorporate conformal radiation therapy with more active, less toxic chemotherapeutic agents should be investigated.

Concomitant @entity1487 , @entity1862 and @entity900 with external beam radiation therapy for locally advanced XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity788 :: ('MESH:D010190', 'Disease') :: ['pancreatic adenocarcinoma'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'toxicities'] @entity390 :: ('MESH:D009325', 'Disease') :: ['nausea'] @entity410 :: ('MESH:D012640', 'Disease') :: ['seizures'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia'] @entity1862 :: ('MESH:D006918', 'Chemical') :: ['hydroxyurea'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity391 :: ('MESH:D014839', 'Disease') :: ['vomiting'] @entity33 :: ('MESH:D052016', 'Disease') :: ['mucositis'] @entity448 :: ('MESH:D000855', 'Disease') :: ['anorexia'] @entity1150 :: ('MESH:D020246', 'Disease') :: ['deep venous thrombosis'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia'] @entity8566 :: ('MESH:D060831', 'Disease') :: ['hand-foot syndrome'] @entity393 :: ('MESH:D034381', 'Disease') :: ['hearing loss'] @entity1487 :: ('MESH:D005472', 'Chemical') :: ['5-fluorouracil']
@entity788 :: (MESH:D010190,Disease) :: ['pancreatic cancer']
